Regeneron CEO Leonard Schleifer on pharma innovation and American entrepreneurship

Bullish Gator

Schleifer discusses Regeneron’s pharmaceutical innovations and how American entrepreneurial spirit fueled the company’s growth.

Editorial companion

What stands out

Leonard Schleifer spent his CNBC interview telling the story of Regeneron's decades-long push to turn scientific bets into medicines, and tying that record to America's entrepreneurial energy. For investors this matters because Regeneron is both a science company and a culture, and the CEO's framing highlights why management keeps funding research and development (R&D) instead of chasing short-term financial engineering. That strategy shows up in steady revenue growth around 5.7% and very modest net income gains near 1.6%.